{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.61","upperLimit":"4.70","value":"2.27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Median duration of survival without disease progression, calculated as on-study date to date of progression or date of death (censored) or off-study date (censored)","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.","id":"OG000","title":"Bortezomib; Docetaxel"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"7.55 months (average duration, on study to off study)","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Month"}